Amgen's Vectibix meets goal in pivotal first-line trial in colorectal cancer
This article was originally published in Scrip
Executive Summary
Amgen's EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), has met its primary progression-free survival (PFS) endpoint in its pivotal Phase III trial, PRIME, in patients with newly diagnosed metastatic colorectal cancer (mCRC) who have a wild-type KRAS gene.